KROS Latest News, Press Relases and Analysis

All

Press Releases

10 days ago - By: Keros Therapeutics, Inc.

Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital

2 months ago - By: Keros Therapeutics, Inc.

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

2 months ago - By: ADAR1 Capital Management, LLC

ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment

2 months ago - By: Keros Therapeutics, Inc.

Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy

3 months ago - By: Zacks Investment Research - Mentions: YMAB

Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates

3 months ago - By: Keros Therapeutics, Inc.

Keros to Exclusively Prioritize the Clinical Advancement of KER-065

3 months ago - By: Keros Therapeutics, Inc.

Keros Therapeutics Reports Second Quarter 2025 Financial Results

5 months ago - By: Yahoo Finance - Mentions: MSFT DUOL ATEN ASML ...

Billionaire has a three-word blunt response to the falling dollar

5 months ago - By: Yahoo Finance - Mentions: BAC VZ ARCB LMNR ...

Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst

5 months ago - By: Benzinga

Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst

5 months ago - By: Yahoo Finance - Mentions: RY RY.CA BA BAC ...

Equity Markets Rise Intraday as US-China Trade Talks Continue

5 months ago - By: Yahoo Finance - Mentions: RJF LMNR MCD EGBN ...

McDonald's downgraded on GLP-1 drug worries: Wall Street's top analyst calls

5 months ago - By: ADAR1 Capital Management, LLC

ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal

5 months ago - By: Keros Therapeutics, Inc.

Keros Announces Return of $375 Million in Excess Capital to Stockholders

5 months ago - By: Keros Therapeutics, Inc.

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference

5 months ago - By: Yahoo Finance - Mentions: KR

C&S ventures into international supply chain market with new partnership

5 months ago - By: Yahoo Finance - Mentions: CADL PFE VREX CTKB ...

Candel Therapeutics, Inc. (CADL)’s CAN-2409 Advances with FDA RMAT Status for Localized Prostate Cancer

5 months ago - By: Yahoo Finance - Mentions: CTKB MS PFGC CRM ...

Cytek Biosciences, Inc. (CTKB) Elevates Cell Analysis with New Aurora Evo System

5 months ago - By: Yahoo Finance - Mentions: PFE CADL XRX KC ...

Pfizer Inc. (PFE) Ends Acepodia Partnership Amid Depo-Provera Legal Woes

5 months ago - By: Yahoo Finance - Mentions: REVB ESLT CTKB VREX ...

Revelation Biosciences, Inc. (REVB) Raises $4M in Public Offering

5 months ago - By: Yahoo Finance - Mentions: VREX CTKB CADL CI ...

Varex Imaging Corporation (VREX) Downgraded by S&P as Regulatory Outlook Remains Cloudy

5 months ago - By: Yahoo Finance - Mentions: VRNA NEXT VFC SONY ...

Jim Cramer Notes Verona Pharma plc (VRNA) “Loses a Lot of Money”

5 months ago - By: Yahoo Finance - Mentions: NPCE IVVD ENPH HOWL ...

H.C. Wainwright Initiates Coverage of NeuroPace (NPCE) With Buy Rating

5 months ago - By: Yahoo Finance - Mentions: IVVD NPCE HOWL THC ...

H.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue Shortfall

5 months ago - By: Benzinga - Mentions: MRK

Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45%

5 months ago - By: Yahoo Finance - Mentions: MRK TGT

Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45%

5 months ago - By: Keros Therapeutics, Inc.

Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring

5 months ago - By: Keros Therapeutics, Inc.

Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros’ Director Nominees

5 months ago - By: ADAR1 Capital Management LLC

ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth

6 months ago - By: ADAR1 Capital Management LLC

ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth

6 months ago - By: Keros Therapeutics, Inc.

Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference

6 months ago - By: Keros Therapeutics, Inc.

Keros Reinforces Commitment to Maximizing Stockholder Value

6 months ago - By: ADAR1 Capital Management LLC

ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders

6 months ago - By: Zacks Investment Research - Mentions: KMDA

Keros Therapeutics, Inc. (KROS) Q1 Earnings and Revenues Beat Estimates

6 months ago - By: Keros Therapeutics, Inc.

KEROS THERAPEUTICS INC (KROS) Stock News

KROS Latest News, Press Relases and Analysis

Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment

Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy

Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates

Keros to Exclusively Prioritize the Clinical Advancement of KER-065

Keros Therapeutics Reports Second Quarter 2025 Financial Results

Billionaire has a three-word blunt response to the falling dollar

Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst

Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst

Equity Markets Rise Intraday as US-China Trade Talks Continue

McDonald's downgraded on GLP-1 drug worries: Wall Street's top analyst calls

ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal

Keros Announces Return of $375 Million in Excess Capital to Stockholders

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference

C&S ventures into international supply chain market with new partnership

Candel Therapeutics, Inc. (CADL)’s CAN-2409 Advances with FDA RMAT Status for Localized Prostate Cancer

Cytek Biosciences, Inc. (CTKB) Elevates Cell Analysis with New Aurora Evo System

Pfizer Inc. (PFE) Ends Acepodia Partnership Amid Depo-Provera Legal Woes

Revelation Biosciences, Inc. (REVB) Raises $4M in Public Offering

Varex Imaging Corporation (VREX) Downgraded by S&P as Regulatory Outlook Remains Cloudy

Jim Cramer Notes Verona Pharma plc (VRNA) “Loses a Lot of Money”

H.C. Wainwright Initiates Coverage of NeuroPace (NPCE) With Buy Rating

H.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue Shortfall

Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45%

Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45%

Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring

Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros’ Director Nominees

ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth

ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth

Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference

Keros Reinforces Commitment to Maximizing Stockholder Value

ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders

Keros Therapeutics, Inc. (KROS) Q1 Earnings and Revenues Beat Estimates

Keros Therapeutics Reports Recent First Quarter 2025 Financial Results